◎ Sugi Atlas

Atlas / Drug / Ranibizumab

Ranibizumab

drug
On this page

Also known as BCD-300ByoovizCimerliFAB-12 VARIANT Y0317FYB-201FYB201LucentisPF-582Pf-582 (ranibizumab biosimilar)Pf582QL-1205QL1205Ranibizumab biosimilar pf582Ranibizumab eqrnRanibizumab nunaRanibizumab-eqrnRanibizumab-nunaRanivisioRG-3645

Summary

Ranibizumab (CHEMBL1201825) is an approved antibody (ATC S01LA04); indicated across 33 conditions including diabetic retinopathy and degenerative myopia.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: S01LA04
  • Indications: 33 conditions
  • Clinical trials: 451

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201825
NameRanibizumab
TypeAntibody
Max phase4
ATCS01LA04

Also known as: BCD-300, Byooviz, Cimerli, FAB-12 VARIANT Y0317, FYB-201, FYB201, Lucentis, PF-582, Pf-582 (ranibizumab biosimilar), Pf582, QL-1205, QL1205

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

33 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
diabetic retinopathy4MONDO:0005266EFO:0003770
degenerative myopia4MONDO:0001383HP:0000545
ocular vascular disorder4MONDO:0005552EFO:0005753
wet macular degeneration4MONDO:0005417EFO:0004683
choroidal neovascularization4MONDO:0810000MONDO:0810000
age-related macular degeneration3MONDO:0005150EFO:0001365
retinal vein occlusion3MONDO:0006951EFO:1001157
retinopathy of prematurity3MONDO:0006952EFO:1001158
neovascular glaucoma3MONDO:0019783EFO:1001060
macular degeneration3MONDO:0003004EFO:0009606
blindness (disorder)3MONDO:0001941MONDO:0001941
glaucoma3MONDO:0005041MONDO:0005041
uveal melanoma3MONDO:0006486EFO:1000616
retinal disorder2MONDO:0005283EFO:0003839
diabetes mellitus2MONDO:0005015EFO:0000400
pterygium2MONDO:0005085EFO:0000678
histoplasmosis2MONDO:0018312EFO:0007310
retinal detachment2MONDO:0008375EFO:0005773
telangiectasis2MONDO:0001576MONDO:0001576
retinoblastoma2MONDO:0008380MONDO:0008380
corneal neovascularization1MONDO:0006713EFO:1000880
anterior ischemic optic neuropathy1MONDO:0006649EFO:1000809
open-angle glaucoma1MONDO:0005338EFO:0004190
angioid streaks1MONDO:0011782EFO:1000805
central serous chorioretinopathy1MONDO:0018616EFO:0009784
von Hippel-Lindau disease1MONDO:0008667MONDO:0008667

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 451.

Phase distribution

PhaseTrials
PHASE3102
PHASE490
PHASE287
Not specified69
PHASE1/PHASE240
PHASE140
PHASE2/PHASE321
EARLY_PHASE12

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00423189PHASE4TERMINATEDLucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
NCT00473642PHASE4COMPLETEDReduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
NCT00504959PHASE4COMPLETEDSafety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT00533520PHASE4COMPLETEDEvaluation of Dosing Interval of Higher Doses of Ranibizumab
NCT00540930PHASE4UNKNOWNIntravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
NCT00674323PHASE4COMPLETEDEfficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
NCT00680498PHASE4COMPLETEDCombination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
NCT00682539PHASE4COMPLETEDIntraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema
NCT00813891PHASE4UNKNOWNEfficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
NCT01006538PHASE4COMPLETEDMacular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
NCT01027481PHASE4COMPLETEDRanibizumab in Patients With Branch Retinal Vein Occlusion
NCT01127360PHASE4COMPLETEDLUCAS (Lucentis Compared to Avastin Study)
NCT01148511PHASE4COMPLETEDComparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)
NCT01213667PHASE4UNKNOWNGenetics in Non-response to Anti-VEGF Treatment in Exudative AMD
NCT01223612PHASE4COMPLETEDLucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation
NCT01246089PHASE4UNKNOWNRanibizumab for Myopic Neovascularization
NCT01257815PHASE4COMPLETEDRanibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
NCT01277302PHASE4COMPLETEDA Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
NCT01297569PHASE4COMPLETEDRanibizumab Treat and Extend in Diabetic Macular Edma
NCT01306981PHASE4COMPLETEDRanibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study
NCT01315275PHASE4COMPLETEDA Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema
NCT01319188PHASE4TERMINATEDRanibizumab and the Risk of Arterial Thromboembolic Events
NCT01427751PHASE4COMPLETEDSafety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
NCT01448018PHASE4COMPLETEDHemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
NCT01453920PHASE4COMPLETEDWet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing
NCT01464723PHASE4COMPLETEDStudy EvAluating Genotypes While Using Lucentis 2
NCT01500915PHASE4COMPLETEDFUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
NCT01628354PHASE4COMPLETEDStudy to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
NCT01669447PHASE4UNKNOWNEvaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis
NCT01710839PHASE4COMPLETEDWidefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
NCT01775124PHASE4COMPLETEDEfficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
NCT01795209PHASE4TERMINATEDRanibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
NCT01810042PHASE4COMPLETEDIndocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
NCT01827722PHASE4UNKNOWNOzurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
NCT01831947PHASE4COMPLETEDEfficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01846273PHASE4COMPLETEDVisual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
NCT01922154PHASE4COMPLETEDIntravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
NCT01958918PHASE4COMPLETEDEfficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
NCT01972789PHASE4COMPLETEDComparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
NCT01986907PHASE4COMPLETEDSafety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 15

This page pulls from 15 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem